ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% – Tale of the Tape

None of the estimates for this stock were revised in the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

ChemoCentryx carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

However, some better-ranked stocks in the med-drugs industry include Ampio Pharmaceuticals, Inc. (AMPE), Cempra, Inc. (CEMP) and Enanta Pharmaceuticals, Inc. (ENTA) ), all sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>